Known targets — ChEMBL curated mechanism
BRAFFLT1FLT3FLT4KDRKITPDGFRBRAF1RET
The experimentally established mechanism targets of Cm-4307. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 0.88 |
| ▸ | KDR known ✓ | P35968 | 5/20 | 0.88 |
| ▸ | BRAF known ✓ | P15056 | 4/20 | 0.88 |
| ▸ | RET known ✓ | P07949 | 3/20 | 0.88 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.88 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.88 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.88 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.88 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.88 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.88 |
| ▸ | ABL1 | P00519 | 2/20 | 0.88 |
| ▸ | HTR1A | P08908 | 2/20 | 0.88 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.88 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.88 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.88 |
| ▸ | MAOA | P21397 | 2/20 | 0.88 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.88 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.88 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cm-4307 SCHEMBL30172564 | 1.00 | RAF1 (0.88) | RAF1KDRBRAFRETRIPK2 | |
| Cm-4307 SCHEMBL29362075 | 1.00 | RAF1 (0.88) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL14481281 | 0.95 | RAF1 (0.89) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL14481164 | 0.94 | RAF1 (0.88) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL14550501 | 0.94 | RAF1 (0.77) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL8218 | 0.93 | RAF1 (1.00) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL29349634 | 0.93 | RAF1 (1.00) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL14739751 | 0.93 | RAF1 (1.00) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL1533976 | 0.93 | RAF1 (0.98) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL1533982 | 0.93 | RAF1 (0.98) | RAF1KDRBRAFRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3330254-A2 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2018-06-06 | — | — | EP | claimed |
| EP-2548868-B1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA -DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO LTD (CN) | 2018-01-24 | — | — | EP | claimed |
| US-8669369-B2 | Method and process for preparation and production of deuterated Ω-diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2014-03-11 | — | — | US | claimed |
| EP-2548868-A1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED -DIPHENYLUREA | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2013-01-23 | — | — | EP | claimed |
| US-20130012548-A1 | DEUTERIUM-SUBSTITUTED OMEGA-DIPHENYLUREA AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2013-01-10 | — | — | US | claimed |
| EP-3330254-A2 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2018-06-06 | — | — | EP | disclosed |
| EP-2548868-B1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA -DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO LTD (CN) | 2018-01-24 | — | — | EP | disclosed |
| US-9078933-B2 | Deuterated omega diphenylurea related compounds and intermediates | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2015-07-14 | — | — | US | disclosed |
| US-9072796-B2 | Method for preparing deuterated diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2015-07-07 | — | — | US | disclosed |
| US-20150175545-A1 | Preparation Method of Fluoro-Substituted Deuterated Diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO LTD (CN) | 2015-06-25 | — | — | US | disclosed |
| EP-2548859-B1 | PREPARATION METHODS OF METHYL-D3-AMINE AND SALTS THEREOF | SUZHOU ZELGEN BIOPHARMACEUTICAL CO LTD (CN) | 2015-03-04 | — | — | EP | disclosed |
| US-8759531-B2 | Preparation method of fluoro-substituted deuterated diphenylurea | Suzhou Zelgen Biopharmaccceutical Co., Ltd. (CN) | 2014-06-24 | — | — | US | disclosed |
| US-20130035492-A1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. | 2013-02-07 | — | — | US | disclosed |
| EP-2548867-A1 | METHOD FOR PREPARING DEUTERATED DIPHENYLUREA | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2013-01-23 | — | — | EP | disclosed |
| EP-2548859-A1 | PREPARATION METHODS OF METHYL-D3-AMINE AND SALTS THEREOF | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2013-01-23 | — | — | EP | disclosed |
| EP-2548868-A1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED -DIPHENYLUREA | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2013-01-23 | — | — | EP | disclosed |
| US-20130018209-A1 | PREPARATION METHODS OF METHYL-D3-AMINE AND SALTS THEREOF | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2013-01-17 | — | — | US | disclosed |
| US-20130018209-A1 | PREPARATION METHODS OF METHYL-D3-AMINE AND SALTS THEREOF | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2013-01-17 | — | — | US | disclosed |
| US-20130012548-A1 | DEUTERIUM-SUBSTITUTED OMEGA-DIPHENYLUREA AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2013-01-10 | — | — | US | disclosed |
| US-20130012548-A1 | DEUTERIUM-SUBSTITUTED OMEGA-DIPHENYLUREA AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012548-A1 | DEUTERIUM-SUBSTITUTED OMEGA-DIPHENYLUREA AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS | PPARD, HDHD5, SCD | RAF1 2908/4885KDR 1916/4885BRAF 970/4885 |
| US-20130035492-A1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA | PNLIP, PDXK, PNP | RAF1 1962/4885KDR 3367/4885BRAF 881/4885 |
| US-20130018209-A1 | PREPARATION METHODS OF METHYL-D3-AMINE AND SALTS THEREOF | NSD3, CCND3, DRD3 | RAF1 4408/4885KDR 4053/4885BRAF 4110/4885 |
| US-20150175545-A1 | Preparation Method of Fluoro-Substituted Deuterated Diphenylurea | CCND3, UBE2D3, VDR | RAF1 3715/4885KDR 4466/4885BRAF 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.